sathellyv@gmail.com

Bacterial vaginosis (BV), which is the most common vaginal infection among women of reproductive age across the world, results in a disruption of the normal vaginal flora. In the vagina, Lactobacillus species undergo a decrease while anaerobic bacteria, notably Atopobium vaginae and Gardnerella vaginalis, undergo overgrowth. In order to properly treat and prevent complications such as preterm birth, pelvic inflammatory disease, and increased susceptibility to sexually transmitted diseases, it is of utmost importance to get an accurate diagnosis of bacterial vaginosis (BV) [1].

The prevalence rates of bacterial vaginosis range from twenty to fifty percent among women across the globe. These percentages are further divided according on age, ethnicity, and sexual activity. Despite the fact that it is common, accurate laboratory diagnosis is important since many cases do not display any symptoms. A diagnosis that is overlooked or treatment that is delayed might result in negative effects for a woman's reproductive health and gynaecological well-being.

Conventionally, BV is identified by means of:

The development of quantitative polymerase chain reaction (qPCR) assays for bacterial vaginosis (BV) is a direct consequence of advancements in the field of molecular diagnostics. Some of the capabilities of quantitative polymerase chain reaction include the following:

The ability to discover cases in the subclinical or transitional phases, which may escape detection when using more conventional procedures [3].

Despite the fact that conventional procedures are still in broad use, the limitations of these approaches highlight the need of the development of more reliable diagnostic techniques. You may compare quantitative polymerase chain reaction (qPCR) to conventional techniques in order to assess the sensitivity and specificity of molecular testing relative to established processes. Investigate the ways in which qPCR may be incorporated into regular diagnostic methods for clinical applications [4]. Cut down on inconsistencies and enhance treatment outcomes by assisting in the standardization of BV diagnosis for women of reproductive age. This study will compare quantitative polymerase chain reaction with conventional diagnostic procedures in women of reproductive age in order to evaluate the accuracy, specificity, and potential advantages of molecular diagnostics in the improvement of therapeutic therapy for bacterial vaginosis.

The study included 125 women from two Indian gynaecology clinics and a university research lab. Women had to get a normal gynaecological checkup between June and October 2023 to participate. Participants have to be 18 or older and had not used vaginal medication or antibiotics for 14 days. After verbal consent, participants provided two additional vaginal swabs for quantitative polymerase chain reaction (qPCR) testing and graded Gramme stain analysis (Nugent score). Demographic and clinical data such age, pregnancy status, history of recurrent BV, and co-infections were collected anonymously to ensure participant privacy. We utilized non-traceable study numbers. After excluding 15 participants owing to incomplete evaluations, 110 were eligible for research.

The Amsel criteria were applied by clinicians at each location to evaluate vaginal swabs [5]. Vaginal samples were subjected to additional analysis using Nugent Graded Gramme staining at med fusion, in accordance with the approach that was previously described in detail [6].

DNA was extracted in accordance with the standard protocol for total nucleic acid by using an automated COBAS AmpliPrep (CAP) system and a total nucleic acid isolation kit (TNAI kit, Roche Diagnostics). To summarize, the samples were extracted from the cells by gently agitating them, and then 650 microlitres of the sample was eluted in 75 microlitres. For the purpose of amplification, a reaction volume of 25 microlitres was prepared using a combination of ten microlitres of DNA extract and fifteen microlitres of BV master mix. Before the test may begin, the BV master mix reaction mixture is prepared by whipping together 10 μl of PCR-mix-1-FRT Bacterial vaginosis mix and 5 μl of a combination of PCR-mix-2-FRT and polymerase. A total of six controls and calibrators were included in every single batch [7]. The list includes NTC, DNA calibrator FC1, DNA calibrator FC2, BV-NC, BV-PC, and BV-SPC, among others. The information that was gathered was analyzed using clinical correlation using ratio coefficients (RC1, RC2, and RC3) that were obtained for combinations of targets that were evaluated by PCR. This was done using Excel-Macro (see Table 1). If they were accessible, conflicts between the "Nugent Score" and the polymerase chain reaction (PCR) method were resolved by using the Amsel criteria or other tests, such as the BD Affirm test.

The Wilcoxon rank-sum test was used to examine the quantitative distribution of the bacteria in bacterial vaginosis and normal flora. Differential expression was considered to have reached statistical significance when the P value was less than 0.01. When we used a dichotomous primary endpoint that had an error rate of 0.05% and an incidence of 20%, we were able to distinguish venomous infections with more than 80% power. Furthermore, we utilised binary logistic regression analyses (SPSS statistical software, version 22) to contrast the predictive value of specific targets in relation to vaginosis versus normal results. In these analyses, we took into consideration co-infections with other sexually transmitted infections (STIs), including C trachomatis and N gonorrhoea, as well as non-STIs such as yeast. The p-values are below the threshold of 0.001 in both cases. [8] A binary primary endpoint with a 0.05% error rate and a 20% incidence rate enabled us to distinguish between venomous infection and the normal condition with above 80% power. Furthermore, we utilised binary logistic regression analyses (SPSS statistical software, version 22) to contrast the predictive value of specific targets in relation to vaginosis versus normal results. In these analyses, we took into consideration co-infections with other sexually transmitted infections (STIs), including C trachomatis and N gonorrhoea, as well as non-STIs such as yeast. When confounders were taken into account, P values that were less than 0.05 were considered to be significant findings.

 

 

Table 2 displays information on the clinical and demographic characteristics of the study cohort. The ethnic composition of the participants in the research was as follows: 60.91 percent were white, 25.45 percent were Hispanic, and 9.09 percent were African American. The registrants included twelve point seven two percent (12.72%) pregnant women [9]. In 22.72 percent of the subjects, yeast, Chlamydia trachomatis, and Neisseria gonorrhoeae were identified to be the most prevalent co-infections. Recurrence of bacterial vaginosis (BV) was seen in 14.55 percent of the individuals who participated.

The overall agreement between the NUGENT Graded Gramme Stain and the PCR BV test is shown in Table 3. When the Nugent method was used, 36.36 percent of patients were found to have BV, and 15.45 percent of patients were found to have transitional BV. According to the polymerase chain reaction (PCR) method, on the other hand, 48.18 percent of the cases were categorised as BV, whereas 12.72 percent were categorised as either transitional BV or BV of unclear origin [10]. In all, the two techniques exhibited an 81.81 percent degree of agreement with one another. The PCR approach did not overlook any of the instances when the Nugent score was used as the gold standard for designating BV positives. The polymerase chain reaction (PCR) method was used in the determination of the typicality of just two of the Nugent intermediates. The PCR-based BV test was shown to be 10 percent more sensitive than the "Nugent Score" and to identify 10 percent more positive cases. Seven cases of genuine bacterial vaginosis (BV) and five cases of transitional BV were discovered by means of PCR-based BV tests; these cases were considered to be normal according to the NUGENT score.

 

The Amsel criteria and the NUGENT Graded Gramme stain were found to have a total concordance of 64.08 percent, as can be shown in Table 4 [11]. Amsel was not particularly successful, as it had a sensitivity of just 61.70 percent and a specificity of only 78.57 percent.

 

The predictive significance of individual targets for the Normal vs Vaginosis condition is shown in Table 5, which takes into account co-infections with C. trachomatis, N. gonorrhoea, and yeast. The average log copies/mL for GV, AV, Lacto, and total DNA in the normal population were 2.81, 3.38, 7.22, and 7.40, respectively. On the other hand, the BV population had values of 7.20 (p < 0.0001), 7.18 (p < 0.0001), 6.52 (p ≤ 0.01), and 8.11 (p < 0.0001), as can be shown in Figure 1A and Figure 1B. After accounting for any confounding factors, the values remained statistically significant [12].

Quantitative polymerase chain reaction (qPCR) provides a very sensitive and objective method for diagnosing bacterial vaginosis (BV) in women of reproductive age, which is in stark contrast to more conventional procedures such as Nugent score and Amsel criteria. As opposed to traditional morphological assessments, the findings of our research demonstrate that quantitative polymerase chain reaction (qPCR) is more reliable and repeatable when it comes to diagnosing BV and transitional cases. The use of ratio coefficients and total DNA quantification may be of assistance in the standardisation of bacterial variations in order to have a better understanding of the fluctuations that occur in vaginal flora. Furthermore, molecular diagnostics enhance women's health screening by enabling the identification of a variety of illnesses from a single sample all at once. Quantitative polymerase chain reaction (qPCR) is an appealing alternative to conventional bacterial vaginosis (BV) diagnostic techniques due to the fact that it may potentially be standardised, can be more sensitive, and is less subjective. In the management of reproductive health, it may potentially be an asset that is beyond measure in the present day.